Paul frohna
Scientific & Clinical Advisor Vasarya Therapeutics
Dr. Paul Frohna is a physician-scientist with 25 years of biotech experience advancing respiratory and fibrotic disease programs. As former CMO of Endeavor BioMedicines, he led the clinical development of a novel anti-fibrotic therapy for IPF that achieved positive Phase 2a results and designed the Phase 2b WHISTLE-PF trial in IPF. He has also supported multiple biotech programs in pulmonary/multi-organ fibrosis through his consulting work. Earlier roles at FibroGen and Genentech further strengthen his expertise in fibrosis and translational medicine. Dr. Frohna holds an M.D., Ph.D. in Pharmacology, and a Pharmacy degree.
Seminars
Wednesday 30th September 2026
Panel Discussion: Business as Usual or Back to the Drawing Board? Rethinking IPF Trial Design in a Three Antifibrotic Era
11:00 am
- Has the Approval of New Antifibrotics Fundamentally Changed IPF Trial Design? Exploring whether the introduction of additional approved therapies requires a paradigm shift toward combination trials and active comparators, or whether traditional development approaches remain valid
- Managing Background Therapies in an Evolving Standard of Care Debating strategies for incorporating monotherapy, prior antifibrotic exposure, and real-world combination regimens without compromising interpretability or feasibility of clinical trials.
- Lessons from Other Crowded Therapeutic Areas Considering how fields such as inflammatory bowel disease, rheumatoid arthritis, and psoriasis have continued drug development despite multiple approved therapies, and whether ILD should follow a similar path.
- Designing Future Trials as the Pipeline Expands Anticipating how additional approvals may influence eligibility criteria, stratification strategies, and expectations for head-to-head or combination studies.
